Regeneron Pharmaceuticals Inc vs Abbvie Inc.
REGN vs ABBV — side-by-side comparison from reported financials. REGN leads 7, ABBV leads 4 of 11 comparable metrics.
Regeneron Pharmaceuticals Inc
REGN · Healthcare
$745.55+0.81%Mixed
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | REGN | ABBV |
|---|---|---|
| Price | $745.55 | $276.43 |
| Market cap | $76.8B | $488B |
| Revenue (TTM) | $15.5B | $64.4B |
| Revenue growth | +5.6% | +1.8% |
| Net margin | 27.9% | 9.8% |
| Free cash flow | $3.76B | $18.2B |
| Net cash (debt) | $6.62B | ($56.2B) |
| 1-year price return | +30.8% | +19.8% |
| P/E | 17.8 | 77.4 |
| P/E vs own history (cheap-side %) | 46% | 23% |
| Dividend yield | 0.49% | 2.45% |
| Return on equity | 14% | 96% |
| Altman Z-score | — | 2.33 |
| CV checks passed | 10 of 11 | 9 of 11 |
| Employees | 15,410 | 57,000 |
Full résumé-style profiles: REGN CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.